TDP-43 aggregation inhibitors (Heinrich Heine Universitat Dusseldorf/Prosetta BioSciences/AstraZeneca)

N/A

Report date: 2025/03/20 09:55:21
NME

Base Information

Drug NameTDP-43 aggregation inhibitors (Heinrich Heine Universitat Dusseldorf/Prosetta BioSciences/AstraZeneca)
Drug Alias NameTAR DNA-binding protein 43 aggregation inhibitors (Heinrich Heine Universitat Dusseldorf/Prosetta BioSciences/AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTAR DNA binding protein 43 modulators
TargetsTAR DNA binding protein 43
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHeinrich Heine University Dusseldorf
China Registration ClassN/A

Develop Information

Active CompaniesHeinrich Heine University DusseldorfProsetta Biosciences IncAstrazeneca Plc +[4] 
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A